Collaboration - May 4, 2023
Lundbeck and Alloy Therapeutics collaborate
Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and it SeqImmune discovery module, which is a sequence-first workflow for early-on repertoire capture and generation of maximum initial diversity. Lundbeck has licensed Alloy’s ATX-Gx humanized transgenic mouse platform since 2020, and this partnership reflects a deepening of the relationship between the companies, […]
Agreement - April 18, 2023
Genmab and argenx enter collaboration
Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody […]
Agreement - April 17, 2023
Novo Nordisk and Aspect enter partnership
Aspect Biosystems and Novo Nordisk have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s […]
Business - April 10, 2023
The President of Estonia has visited Lund, including MAX IV and ESS
Visiting some of the world’s foremost laboratories in the Swedish city of Lund, President Alar Karis remarked that contributing to their development significantly broadens the horizons of Estonian science, deepens cooperation between researchers and makes new study methods available to them. “Many of the methods used in contemporary science only become available when countries jointly […]
Biotech Business - March 28, 2023
Salipro publishes results from collaboration with AstraZeneca
The study describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. For this study, the teams leveraged GeneArt Gene-to-Protein Services, part of Thermo Fisher Scientific, for protein production with structure determination support from […]
Agreement - March 27, 2023
Orion and Bayer expand clinical development program
Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have […]
